MAJIC, MAKING ADVANCES AGAINST JAUNDICE IN INFANT CARE
MAJIC,在婴儿护理领域对抗黄疸取得进展
基本信息
- 批准号:2892894
- 负责人:
- 金额:$ 1.27万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1998
- 资助国家:美国
- 起止时间:1998-05-01 至 2003-04-30
- 项目状态:已结题
- 来源:
- 关键词:behavioral /social science research tag bilirubin clinical research decision making health care personnel performance health care quality health care service evaluation health insurance health services research tag health surveys home health care hospital length of stay human subject hyperbilirubinemia interview maternal behavior model design /development neonatal transient jaundice newborn human (0-6 weeks) parents paternal behavior physicians
项目摘要
This project will develop and evaluate a model for a Collaborative
Quality Improvement Program in loosely structured managed care
organizations (MCOs). Most quality improvement initiatives for
hospitals or MCOs have occurred in tightly managed systems. This model
addresses how MCOs can fulfill their responsibility for quality
improvement among professionals and organizations with whom they have
contractual leverage but not direct control. The model will be tested
by application to the American Academy of Pediatrics clinical practice
guideline for the care of the healthy term newborn with jaundice.
Two large managed care organizations will partner with the core research
team, enlisting specific patient care units - organizations and
professionals responsible for the continuum of care for a baby during
the first month of life - to participate. The MCOs will conduct and
evaluate two rounds of collaborative QI, each focusing on a distinct
perspective on quality. In the first, the MCO will focus on improving
clinical performance from the professional perspective. In the second,
the focus will be improving the parents experience of receiving care
for their newborn. The relationship between clinical and consumer
perspectives will be explored to test whether clinically excellent
providers are more or less successful in providing a high quality
patient experience.
Clinical performance will be assessed by measuring conformance with
selected guideline recommendations for infants with an elevated serum
bilirubin level. Data for clinical performance measurement will be
obtained from administrative sources (claims, encounter and laboratory
databases), the infant's inpatient medical record and if necessary the
infant's ambulatory medical record. The parental experience of care
will be assessed by a telephone survey of parents, with questions
adapted from the AHCPR's Consumer Assessment of Health Plans Survey
(CAHPS) to apply to the baby's first month of life and care for
jaundice. Approximately 2,200 study-eligible infants are anticipated
across the two participating MCOs.
Parental experience and clinical performance data will be fed back to
the MCOs on a quarterly basis to stimulate and guide QI efforts. Each
MCO will collaborate with the other on exchange of performance data, of
best practices for patient care, and of quality improvement ideas.
They will also be aided in implementing additional, MCO-specific QI
interventions.
An overall summative evaluation of the effect of the five-year
Collaborative QI Program will be conducted. In addition, clinical and
parent experience data relating to the same baby will be paired for
analyses of the convergence and divergence between the performance of
patient care units. Finally, descriptions of the performance measures
based on clinical performance and parent experie nce data, together with
sample results, will be used to elicit an evaluation by independent
panels of purchasers, consumers and physicians of the usefulness of
these two types of measures.
这个项目将开发和评估一个协作的模型
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
R H PALMER其他文献
R H PALMER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('R H PALMER', 18)}}的其他基金
MAJIC, MAKING ADVANCES AGAINST JAUNDICE IN INFANT CARE
MAJIC,在婴儿护理领域对抗黄疸取得进展
- 批准号:
2910704 - 财政年份:1998
- 资助金额:
$ 1.27万 - 项目类别:
MAJIC, MAKING ADVANCES AGAINST JAUNDICE IN INFANT CARE
MAJIC,在婴儿护理领域对抗黄疸取得进展
- 批准号:
6588767 - 财政年份:1998
- 资助金额:
$ 1.27万 - 项目类别:
MAJIC, MAKING ADVANCES AGAINST JAUNDICE IN INFANT CARE
MAJIC,在婴儿护理领域对抗黄疸取得进展
- 批准号:
2668796 - 财政年份:1998
- 资助金额:
$ 1.27万 - 项目类别:
MAJIC, MAKING ADVANCES AGAINST JAUNDICE IN INFANT CARE
MAJIC,在婴儿护理领域对抗黄疸取得进展
- 批准号:
6449755 - 财政年份:1998
- 资助金额:
$ 1.27万 - 项目类别:
MAJIC, MAKING ADVANCES AGAINST JAUNDICE IN INFANT CARE
MAJIC,在婴儿护理领域对抗黄疸取得进展
- 批准号:
6391068 - 财政年份:1998
- 资助金额:
$ 1.27万 - 项目类别:
MAJIC, MAKING ADVANCES AGAINST JAUNDICE IN INFANT CARE
MAJIC,在婴儿护理领域对抗黄疸取得进展
- 批准号:
6185425 - 财政年份:1998
- 资助金额:
$ 1.27万 - 项目类别:
MAJIC, MAKING ADVANCES AGAINST JAUNDICE IN INFANT CARE
MAJIC,在婴儿护理领域对抗黄疸取得进展
- 批准号:
6314289 - 财政年份:1998
- 资助金额:
$ 1.27万 - 项目类别:
MAJIC, MAKING ADVANCES AGAINST JAUNDICE IN INFANT CARE
MAJIC,在婴儿护理领域对抗黄疸取得进展
- 批准号:
6538162 - 财政年份:1998
- 资助金额:
$ 1.27万 - 项目类别:
MEASURING EFFECTIVENESS OF CLINICAL MANAGEMENT SYSTEMS
衡量临床管理系统的有效性
- 批准号:
3372123 - 财政年份:1990
- 资助金额:
$ 1.27万 - 项目类别:
MEASURING EFFECTIVENESS OF CLINICAL MANAGEMENT SYSTEMS
衡量临床管理系统的有效性
- 批准号:
3372124 - 财政年份:1990
- 资助金额:
$ 1.27万 - 项目类别:
相似海外基金
Bilirubin Catabolism induces Plasminogen-Activator Inhibitor 1 (PAI-1) worsening Metabolic Dysfunction
胆红素分解代谢诱导纤溶酶原激活剂抑制剂 1 (PAI-1) 恶化代谢功能障碍
- 批准号:
10750132 - 财政年份:2024
- 资助金额:
$ 1.27万 - 项目类别:
The study for protection from neonatal bilirubin encephalopathy using humanized UGT1A mice
使用人源化 UGT1A 小鼠预防新生儿胆红素脑病的研究
- 批准号:
23K07288 - 财政年份:2023
- 资助金额:
$ 1.27万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Aryl hydrocarbon receptor and bilirubin as therapeutic target for ICH
芳烃受体和胆红素作为脑出血的治疗靶点
- 批准号:
10615880 - 财政年份:2021
- 资助金额:
$ 1.27万 - 项目类别:
Evaluation of a New Method of Bilirubin Screening for Biliary Atresia
胆红素筛查胆道闭锁新方法的评价
- 批准号:
10194633 - 财政年份:2021
- 资助金额:
$ 1.27万 - 项目类别:
Evaluation of a New Method of Bilirubin Screening for Biliary Atresia
胆红素筛查胆道闭锁新方法的评价
- 批准号:
10379379 - 财政年份:2021
- 资助金额:
$ 1.27万 - 项目类别:
Mechanism of Bilirubin-induced Apnea in Preterm Infants
胆红素诱发早产儿呼吸暂停的机制
- 批准号:
10494280 - 财政年份:2021
- 资助金额:
$ 1.27万 - 项目类别:
Mechanism of Bilirubin-induced Apnea in Preterm Infants
胆红素诱发早产儿呼吸暂停的机制
- 批准号:
10373330 - 财政年份:2021
- 资助金额:
$ 1.27万 - 项目类别:
Aryl hydrocarbon receptor and bilirubin as therapeutic target for ICH
芳烃受体和胆红素作为脑出血的治疗靶点
- 批准号:
10299427 - 财政年份:2021
- 资助金额:
$ 1.27万 - 项目类别:
Aryl hydrocarbon receptor and bilirubin as therapeutic target for ICH
芳烃受体和胆红素作为脑出血的治疗靶点
- 批准号:
10408850 - 财政年份:2021
- 资助金额:
$ 1.27万 - 项目类别: